SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data presented at the World Muscle Society, showing slower upper-limb decline after patients switched to deramiocel, has fueled renewed attention to Capricors Duchenne muscular dystrophy therapy. Traders are encouraged by the results but debate whether they will overcome the FDAs prior efficacy and statistical-analysis concerns ahead of its review decision.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, drove the sharp rally and renewed analyst attention. Traders are broadly bullish and discussing a possible short squeeze, while some caution that the move may be overextended and debate dilution risk ahead of lung-cancer data.

Goodyear Tire & Rubber Co. engages in the development, manufacture, distribution, and sale of tires. It operates through the following geographical segments: Americas, Europe, Middle East, and Africa, and Asia Pacific. The Americas segment is involved in the development, manufacture, distribution, and sale of tires and related products and services in North, Central, and South America. The Europe, Middle East, and Africa segment focuses on the development, manufacture, distribution, and sale of tires for automobiles, trucks, buses, aircraft, motorcycles, earthmoving, mining, and industrial equipment throughout Europe, the Middle East, and Africa. The Asia Pacific segment refers to the development, manufacture, distribution, and sales of tires for automobiles, trucks, buses, aircraft, farm, earthmoving, mining, and industrial equipment throughout the Asia Pacific region. The company was founded by Frank A. Seiberling on August 29, 1898 and is headquartered in Akron, OH.

Goodyear Tire & Rubber Co.

Goodyears prolonged slide toward multi-year lows and intermittent sharp moves have fueled debate over its heavy debt and bankruptcy risk versus its low valuation and short-interest-driven rebound potential. Traders speculate about a buyout or short squeeze, but no specific deal or other confirmed catalyst is established in the discussion.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings sharp selloff is being linked to competition from Kalshi and Polymarket in sports prediction markets, regulatory uncertainty, and concern that added DKeX investment could pressure profits. Traders are divided: bears see rivals taking share, while bulls point to DKeXs rising volume and sportsbook growth as signs DraftKings can compete.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection by the U.S. Armys ALATTIS program to develop next-generation 10 kV silicon-carbide semiconductors is driving attention, with bulls viewing it as technology validation and a potential defense and infrastructure opportunity. Debate centers on the awards undisclosed financial terms and prototype scope: some traders see long-term promise, while others say the initial pop faded without evidence of near-term revenue.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Deutsche Banks upgrade of Netflix to Buy after its steep selloff is drawing attention, with the bullish case emphasizing international engagement and valuation despite concerns about weaker U.S. viewing and competition from YouTube. Traders remain divided: some see the upgrade as support for a rebound, while others argue it does not resolve worries about engagement, content, and persistent selling pressure.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCNs sharp rally has traders watching for a technical breakout and linking the move to broader altcoin momentum. Optimism about further gains is tempered by concerns that the rally could fade; Robinhood and BlackRock-related explanations remain speculation, not confirmed catalysts.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Positive Phase 3 DAYBREAK results for Kodiaks experimental wet AMD treatments, including Zenkudas extended-dosing potential, drove a sharp rally and repricing of the companys prospects. Bulls see the data as a major step toward commercialization, while skeptics question its advantage over existing therapies and warn that Kodiaks cash needs could lead to dilution.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns fiscal Q4 earnings and guidance are the dominant focus, with traders watching for signs that AI-driven HBM demand and tight DRAM/NAND supply can sustain strong growth. Many expect a strong report, while others warn that high expectations and uncertainty over how long the memory upcycle will last could prompt a sell-the-news reaction.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Rising Treasury yields and oil-price pressures tied to Middle East tensions are driving concern that persistent inflation could bring further Fed rate hikes, weighing on the Dow and DIA. Traders are divided between warnings of a deeper market pullback and views that the weakness is a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

AbCellera is drawing attention after JPMorgan initiated coverage with an Overweight rating, citing promising ABCL635 results, while traders focus on the drugs Phase 2 data and a planned detailed presentation. The community is broadly bullish on the menopause-treatment candidate and the companys pipeline, though some caution that efficacy and safety still need validation in larger trials and debate whether the stocks sharp run-up may pull back.

The advance appears tied to JPMorgan initiating coverage with an Overweight rating and a $17 price target, citing promising ABCL635 clinical data and its efficacy, safety, and dosing convenience.

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? 

Equity

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence. 


Biotech And Biomimicry Stocks Lighting Up the Market

Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Ocenico Hotel and Congress Center in Rio de Janeiro, Brazil...

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

AbCellera (Nasdaq: ABCL) announced that the Company will present at the Cantor Global Healthcare Conference on September 9, 2026. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through...

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals' FDA approval and the companies' antibody partnership.read more...

Monday 8/17 Insider Buying Report: ABCL, BPRN

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At AbCellera Biologics, a filing with the SEC revealed that on Wednesday, Director...

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera Biologics Inc. (Nasdaq: ABCL) (AbCellera) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to...

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.read more...

National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.read more...

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Extremely Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.17	--	--	N/A
Q2 '26	-$0.14	-$0.18	-24.75%	MISSED
Q1 '26	-$0.17	-$0.14	18.33%	BEAT
Q4 '25	-$0.13	-$0.03	77.61%	BEAT
Q3 '25	-$0.14	-$0.19	-36.94%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABCL Earnings

Upcoming Earnings: Q3 '26

Historical Earnings